Core Viewpoint - A class action has been filed against PepGen Inc. for allegedly misleading investors regarding the effectiveness and safety of its drug candidate PGN-EDO51, which is intended for treating Duchenne muscular dystrophy [1][2]. Company Overview - PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases [1]. Allegations - The complaint alleges that PepGen failed to disclose critical information about PGN-EDO51, including its lower effectiveness and safety compared to what was communicated to investors [2]. - It is claimed that the CONNECT2 study was either dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating the drug's clinical, regulatory, and commercial prospects [2]. Stock Price Impact - Following a press release on January 29, 2025, which highlighted safety concerns in the CONNECT1 study and FDA issues with the CONNECT2 study, PepGen's stock price dropped by $0.40, or 21.74%, closing at $1.44 per share on January 30, 2025 [3]. - On March 4, 2025, after announcing a voluntary pause of the CONNECT2 study, the stock price fell by $0.53, or 18.86%, closing at $2.28 per share [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against PepGen, with a deadline to file a motion for lead plaintiff by August 8, 2025 [5].

Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was misrepresented as being more effective and safe than it actually is [2]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [2]. - The complaint asserts that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - A class action lawsuit has been filed against PepGen Inc. for alleged violations of the Securities Exchange Act of 1934, concerning misrepresentations about the effectiveness and safety of its lead product candidate, PGN-EDO51 [1][3]. Group 1: Legal Action Details - The complaint was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased PepGen securities between March 7, 2024, and March 3, 2025 [1]. - Investors are encouraged to join the class action lawsuit and can contact the Investor Relations Manager for more information [3][4]. Group 2: Company Background - Bernstein Liebhard LLP, the law firm representing the investors, has recovered over $3.5 billion for its clients since 1993 and has a strong track record in class action litigation [5].

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=153444&from=3 CLASS PERIOD: March 7, 2024 to March ...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submissio ...

A lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired the securities of PepGen between March 7, 2024 and March 3, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG ...

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=152957&from=4CLASS PERIOD: March 7, 2024 to March 3, 2025 ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, bot ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PepGen Inc. securities between March 7, 2024, and March 3, 2025, due to alleged misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overstated clinical and commercial prospects of PGN-EDO51 [5]. - Investors who purchased PepGen securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 8, 2025, to represent the class in the lawsuit [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].